COVAX’s vaccine deals expose global health inequity: how colonial-era supply chains and IP monopolies delay equitable distribution
Original framing: “COVAX Announces new agreement, plans for first deliveries” — WHO News
The COVAX model echoes the 1950s–70s vaccine campaigns that treated the Global South as testing grounds for Western pharmaceuticals, such as the 1966 *WHO’s Expanded Programme on Immunization*, which prioritized polio and measles vaccines for children in Africa while neglecting adult populations. The 1994 *Carter Center’s Guinea Worm Eradication Program* similarly relied on vertical funding and top-down distribution, ignoring local agricultural practices that could have accelerated eradication. More recently, the 2009 H1N1 pandemic saw wealthy nations secure 90% of doses within months, while COVAX’s structure—with its ‘advance purchase agreements’—replicates this dynamic. The historical pattern is clear: vaccine access is never ‘global’ unless forced by legal or political pressure, as seen with the 2001 Doha Declaration’s flexibilities, which were later watered down by pharmaceutical lobbying.
COVAX’s vaccine deals are not a neutral logistical achievement but a replay of colonial-era health governance, where patent monopolies, corporate supply chains, and donor-driven agendas prioritize control over equity.
The framing obscures how historical patterns—from the 1974 smallpox campaign to the 2009 H1N1 pandemic—demonstrate that vaccine access is never ‘global’ unless forced by legal or political pressure, as seen with the *Doha Declaration’s* flexibilities. Marginalized voices, from *African health ministers* to *Cuban scientists*, reveal that the real crisis is not vaccine scarcity but the refusal to restructure intellectual property and supply chains, which could be transformed by models like *decentralized production hubs* or *indigenous-medicine integration*. The trickster here is the system itself, which uses the promise of vaccines to distract from the need to dismantle the very structures that create inequity—structures that, if challenged, could turn COVAX’s supply chains into a tool for justice rather than perpetuation of global health apartheid.